INC.

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

by

SAN DIEGO, June 21, 2023 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on June 20, 2023, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 23,650 … Read more

Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

by

NEW YORK, June 21, 2023 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement … Read more

Tekscan Launches a New, Compact In-Shoe Foot Function and Gait Analysis System

by

NORWOOD, Mass., June 21, 2023 /PRNewswire/ — Tekscan is proud to introduce F-Scan™ GO, the newest product in our award-winning line of gait analysis systems for the biomechanics community. The F-Scan GO allows your subject to enjoy full freedom of movement while you capture their natural in-shoe gait with the highest resolution data in the … Read more

PreCheck Health Services Partners with SD Wellness Center, a Dominican Republic Medical Entity, to Launch NGS Testing

by

MIAMI, June 21, 2023 /PRNewswire/ — PreCheck Health Services, a renowned provider of advanced medical diagnostics, is excited to announce its strategic partnership with a distinguished Dominican Republic medical entity, SD Wellness Center. This collaboration marks a significant milestone for PreCheck Health Services as it expands its operations into the vibrant healthcare market of the … Read more

Intrinsic Therapeutics, Inc. Announces Positive Coverage Policy by Cigna Healthcare for Barricaid Bone-Anchored Annular Closure Device

by

BOSTON, June 21, 2023 /PRNewswire/ — Intrinsic Therapeutics, Inc., a medical device company focused on preventing reherniation and reoperation following lumbar discectomy, announced today that Cigna Healthcare has issued a positive coverage policy for the Barricaid® Bone-Anchored Annular Closure device. Cigna Healthcare represents one of the five largest commercial payors in the US, with an estimated … Read more

Aethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation

by

Research to Confirm the Hemopurifier’s Ability to Remove Harmful Viruses and Exosomes From Harvested Organs SAN DIEGO, June 21, 2023 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is investigating the use of its Hemopurifier® in the … Read more

Cosmetic Implants Market to be Worth $21.2 Billion by 2030: Grand View Research, Inc.

by

SAN FRANCISCO, June 21, 2023 /PRNewswire/ — The global cosmetic implants market size is expected to reach USD 21.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.8% from 2023 to 2030. Increasing demand for aesthetic procedures coupled with rising expenditure … Read more

Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic

by

Lead candidate demonstrates specificity, biologic activity and a favorable safety profile in extensive mouse and non-human primate models Upcoming company presentations at Cellicon Valley ’23 and In Vivo Engineering of Therapeutic Cells Summit PHILADELPHIA, June 21, 2023 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, today announced the presentation of compelling … Read more

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis

by

VYVGART® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) SAN DIEGO, June 20, 2023 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with ENHANZE® for subcutaneous (SC) use for the treatment … Read more

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

by

SAN DIEGO, June 20, 2023 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that on June 20, 2023, non-qualified stock option awards to purchase an aggregate of 40,032 shares of its common stock were granted to one new … Read more